Cargando…

The Evolution of Prognostic Factors in Multiple Myeloma

Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease. Despite improvement in treatment strategies of MM over the last decade, the dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanbali, Amr, Hassanein, Mona, Rasheed, Walid, Aljurf, Mahmoud, Alsharif, Fahad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339490/ https://www.ncbi.nlm.nih.gov/pubmed/28321258 http://dx.doi.org/10.1155/2017/4812637

Ejemplares similares

Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia
por: Abdrabou, Ahmed Kotb, et al.
Publicado: (2021)

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
por: Hassanein, Mona, et al.
Publicado: (2021)

Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patients
por: Alaiya, Ayodele A., et al.
Publicado: (2016)

Improved survival in adolescents and young adults (AYA) patients aged 14–55 years with acute lymphoblastic leukemia using pediatric-inspired protocol – a retrospective analysis of a real-world experience in 79 of patients treated at a national tertiary care referral center
por: Hanbali, Amr, et al.
Publicado: (2021)

Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia
por: Hanbali, Amr, et al.
Publicado: (2023)

Immunological Prognostic Factors in Multiple Myeloma
por: Bębnowska, Dominika, et al.
Publicado: (2021)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
por: El Fakih, Riad, et al.
Publicado: (2018)

Prognostic factors and classification in multiple myeloma.
por: San Miguel, J. F., et al.
Publicado: (1989)

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
por: Binder, M, et al.
Publicado: (2016)

Prognostic and predictive biomarker developments in multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2021)

Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2021)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
por: Wang, Chen, et al.
Publicado: (2020)

Gene expression profiling as a prognostic tool in multiple myeloma
por: Black, Harmony, et al.
Publicado: (2021)

A prognostic index for multiple myeloma.
por: Grignani, G., et al.
Publicado: (1996)

Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies
por: Aljurf, Mahmoud, et al.
Publicado: (2016)

Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time
por: AlYamany, Ruah, et al.
Publicado: (2022)

Brucellosis: Evolution and expected comeback
por: El-Sayed, Amr, et al.
Publicado: (2018)

Conditional survival in multiple myeloma and impact of prognostic factors over time
por: Abdallah, Nadine H., et al.
Publicado: (2023)

Multiple myeloma
por: Collins, Conor D.
Publicado: (2010)

Genome Instability in Multiple Myeloma: Facts and Factors
por: Aksenova, Anna Y., et al.
Publicado: (2021)

Multiple Myeloma of the Orbit
por: Hassan, Mona, et al.
Publicado: (2012)

Diagnostic and Prognostic Value of PACAP in Multiple Myeloma
por: Tóth, Tünde, et al.
Publicado: (2023)

Multiple myeloma: the (r)evolution of current therapy and a glance into the future
por: Gulla', Annamaria, et al.
Publicado: (2020)

PB2156: CLINICAL AND PROGNOSTIC FACTORS IN MULTIPLE MYELOMA IN THE GOMEL REGION
por: Kozich, Zhanna, et al.
Publicado: (2023)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
por: Lebel, Eyal, et al.
Publicado: (2022)

Prognostic significance of FSCN family in multiple myeloma
por: Deng, Cong, et al.
Publicado: (2021)

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
por: Bolli, Niccolo, et al.
Publicado: (2014)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma
por: Solimando, A G, et al.
Publicado: (2018)

Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
por: Nassar, Amr, et al.
Publicado: (2014)

Treatment evolution and improved survival in multiple myeloma in Taiwan
por: Tang, Chao-Hsiun, et al.
Publicado: (2019)

Multiple myeloma/hypercalcemia
por: Oyajobi, Babatunde O
Publicado: (2007)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Integrins in multiple myeloma
por: Hosen, Naoki
Publicado: (2020)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Prognostic significance of esterase gene expression in multiple myeloma
por: Kumari, Romika, et al.
Publicado: (2021)

Molecular and immunological mechanisms of clonal evolution in multiple myeloma
por: Forster, Stefan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ec4fnpdk977c3q0khp3hqa2o6p